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The transient control of diverse biological responses
that occurs in response to varied forms of stress is often
a highly regulated process. During the interferon (IFN)
response, translational repression due to phosphoryla-
tion of eukaryotic initiation factor 2, eIF2, by the
double-stranded RNA-dependent protein kinase, PKR,
constitutes a means of inhibiting viral replication. Here
we show that the transient nature of the IFN response
against acute viral infections is regulated, at least in
part, by RNase L. During the IFN antiviral response in
RNase L-null cells, PKR mRNA stability was enhanced,
PKR induction was increased, and the phosphorylated
form of eIF2 appeared with extended kinetics com-
pared with similarly treated wild type cells. An en-
hanced IFN response in RNase L-null cells was also dem-
onstrated by monitoring inhibition of viral protein
synthesis. Furthermore, ectopic expression of RNase L
from a plasmid vector prevented the IFN induction of
PKR. These results suggest a role for RNase L in the
transient control of the IFN response and possibly of
other cytokine and stress responses.
Negative feedback mechanisms are essential for maintaining
transient responses such as those of the immune response by
attenuating undesirable outcomes resulting from prolonged re-
sponses. Different negative regulatory pathways of interferon
(IFN)1 and cytokine responses exist in mammalian cells such
as those of the suppressors of signals (1) and mRNA turnover
regulation by the AU-rich elements in the 3-untranslated re-
gions (2). The IFN antiviral response is a highly regulated
process involving the transient inhibition of viral and cellular
protein synthesis. The translational inhibition is mediated pre-
dominately by the activity of PKR, the double-stranded RNA-
dependent protein kinase. PKR is a serine/threonine protein
kinase of 65 and 68 kDa in murine and human cells, respec-
tively, that is induced by IFN treatment of cells and phospho-
rylates itself and other proteins, notably eIF2, in response to
viral double-stranded RNA (3). DsRNA is produced as the
replicative intermediates of many RNA viruses and also by
annealing of complementary RNA strands transcribed from
some DNA viruses (3). Phosphorylated eIF2 sequesters the
guanine nucleotide exchange factor, eIF2B, which becomes
trapped as inactive complex with GDP resulting in transla-
tional arrest (4, 5).
Among the principal effectors of the IFN-induced antiviral
state are the 2,5-oligoadenylate (2-5A) synthetases that con-
vert ATP to 2-5A, activators of RNase L, in response to viral
double-stranded RNA (6, 7). Thus, 2-5A is an alarmone that
alerts the cells to the presence of virus by signaling to RNase L.
Both RNase L and PKR have been implicated in the action of
IFN- against a variety of viruses (reviewed in Refs. 8 and 9).
RNase L is widely distributed in different tissues, and it has
been suggested that low levels of 2-5A lead to RNase L-medi-
ated selective degradation of viral mRNA (10), whereas higher
levels may lead to broader effects such as cleavage of 18 S and
28 S ribosomal RNAs (11). During the course of experiments on
the role of RNase L in the inhibition of viral protein synthesis
during acute infections, we observed that an absence of RNase
L led to selective stabilization of PKR mRNA, extended kinetics
of eIF2 phosphorylation, and potent inhibition of viral protein
synthesis. Our findings suggest that RNase L truncates and
limits the induction of PKR, possibly contributing to the tran-
sient nature of the IFN response against viral infections.
EXPERIMENTAL PROCEDURES
Cell Culture, Viral Infections, and IFN Treatments—RNase L/ and
RNase L/ mouse embryonic fibroblast (MEF) cell lines were of mixed
or C57BL/6 genetic backgrounds. The cell lines are post-crisis deriva-
tives of primary MEFs as described previously (12). MEFs were cul-
tured in DMEM with high glucose supplemented with 10% FBS and
antibiotics (Invitrogen, Gaithersburg, MD). Bone marrow macrophages
collected from the femurs of RNase L/ and RNase L/ mice, both on
a background of C57BL/6, were cultured in L-cell-conditioned medium
for 8 days and plated at a density of 106 cells per 10-cm plate. WISH cell
line (HeLa markers) was obtained from the American Type Culture
Collection (ATCC, Rockville, MD) and cultured in RPMI 1640 supple-
mented with 10% FBS and antibiotics.
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Encephalomyocarditis virus (EMCV) and vesicular stomatitis virus
(VSV, Indiana strain) were obtained from the ATCC (Manassas, VA).
Virus preparations were clarified by low speed centrifugation, filtered
through 0.22-m membranes for sterility, and titrated on VERO (Afri-
can Green Monkey Kidney cell line, ATCC) with resultant titers of 2 
109 and 8  108 plaque forming units/ml for EMCV and VSV, respec-
tively. Viruses were aliquoted and stored at 70 °C until use.
Hybrid IFN- BBDB, equally active on mouse and human cells, was
a generous gift from H. K. Hochkeppel (Norvatis Pharma AG) (13). The
specific activity, determined by titrating on human amnion cells
(WISH) calibrated with National Institutes of Health standard IFN,
Gxa01-901-535, was 1.3 109 IU/mg using the manufacturer’s reported
amount of pure IFN weight.
Monitoring Phosphorylation of the  Subunit of eIF2—Cells were
incubated with or without IFN- (1000 units/ml). Proteins were ex-
tracted in ice-cold lysis buffer. Kinase reactions were in 20 mM Tris-
HCl, pH 7.5, 0.3 mg/ml BSA, 5% glycerol, 100 IU aprotinin, 10 M
EDTA, 50 mM KCl, 2 mM MgCl, 2 mM MnCl2, 100 M ATP, and 100
ng/ml of poly(I)poly(C) and incubated at 30 °C for 30 min. To monitor
eIF2 levels, cells were incubated with or without IFN- and infected
with EMCV (m.o.i.  10) for 0.5, 1, 2, or 4 h followed by lysing the cells
in ice-cold lysis buffer. Proteins were separated on SDS-10% acrylamide
gels and transferred to polyvinylidene difluoride membranes (Bio-Rad,
Richmond, CA). Membranes were blocked with buffer containing 2%
BSA/0.5% Tween-20 and probed with anti-phospho-eIF2- antiserum
(Cell Signaling Technology, Beverly, MA) by incubating the membrane
overnight at 4 °C with antibody diluted in the blocking buffer. The
antibody specifically detects eIF2 only when phosphorylated at serine
51, because the antibody was raised against a peptide corresponding
to residues surrounding Ser-51 of human eIF2. Secondary antibody
(anti-rabbit IgG labeled with horseradish peroxidase) was used for
immunodetection and visualization (ECL, Amersham Biosciences,
Buckingham, UK). Rabbit Antibodies to total eIF (Santa Cruz Biotech-
nology) were also used to probe Western blots.
Monitoring Viral Protein Synthesis—IFN-mediated inhibition of vi-
ral protein synthesis was determined in the presence of actinomycin D
to selectively inhibit cellular transcription and thereby reduce cellular
protein synthesis. Confluent MEFs (2  105 cells per well) in 24-well
plates (Linbro, Flow Laboratories) were incubated in maintenance me-
dium (DMEM plus 2% FBS) in the absence or presence of IFN- at 1000
units/ml for 20 h. EMCV was incubated with the cells for 1 h. Unad-
sorbed virus was removed, and cells were incubated for 4 h with main-
tenance medium containing 5 g/ml of actinomycin D (Sigma, St. Louis,
MO). The medium was replaced with cysteine/methionine-free medium
supplemented with 6 Ci of [35S]cysteine/methionine (Promix, Amer-
sham Biosciences). The cells were incubated for a further 1.5 h, media
were removed, and proteins were extracted in gel sample buffer.
Infectious Virus Yield Assays—Confluent cells were infected for 1 h,
unadsorbed virus was removed by washing monolayers with PBS con-
taining 2% FBS, and infections were continued in DMEM with high
glucose supplemented with 5% FBS and antibiotics. Cell lysates were
obtained by repeated freezing and thawing, and supernatants (contain-
ing both intracellular and extracellular viral particles) were collected
after centrifugation at 300  g at 4 °C. Infectious virus in the clarified
supernatants were quantitated by plaque assays after titration on
confluent monolayers of VERO cells grown in 24-well plates with over-
lay MEM medium containing agar (Sigma). The plates were fixed and
stained with crystal violet, and plaques were counted.
Immunoprecipitations and Autophosphorylation of PKR—Confluent
cells (4  10 5 cells per well) in 12-well tissue culture dishes (Linbro)
were incubated with or without IFN- (1000 units/ml) for different
periods of time. Cultures were incubated for 24 h in methionine-free
minimal essential medium (Invitrogen) supplemented with 2% dialyzed
FBS and 10 Ci of [35S]methionine (Amersham Biosciences). After
washing, cells were lysed in buffer containing 1% Triton X-100. Lysates
were incubated with anti-PKR antibody (Santa Cruz; 1/250 dilution),
and immune complexes containing PKR were immobilized on protein-
A-Sepharose beads (Amersham Biosciences) for 1 h at 4 °C. PKR was
eluted by boiling in gel sample buffer and incubated with [-32P]ATP
and poly(dI)poly(dC) in a kinase reaction buffer for 30 min.
SDS-PAGE—Equal amounts, as determined by the Bradford method
(Bio-Rad, Richmond, CA), of proteins or equal amounts of the immuno-
precipitation lysates were electrophoresed in 12% SDS-PAGE gels. The
gels were fixed overnight, washed, dried, and visualized by autoradiog-
raphy (Kodak XAR film, Kodak, Rochester, NY) at 70 °C. Protein
molecular weight markers (14C-methylated, 14–220 kDa) were used to
verify the size of viral proteins. In the case of phosphorylated STAT-1,
protein was visualized using the ECL chemiluminescence kit (Amer-
sham Biosciences).
Assay of PKR Levels in Mice Treated with IFN-—Female RNase
L/ (Jackson Lab, C57/bl6) and female RNase L/ (C57/bl6) mice at
10 weeks of age were injected by the intraperitoneal route with 5  105
units of IFN- (BBDB) in 200 l of PBS. Organs (spleen and thymus)
were removed from sacrificed mice that were either untreated or IFN-
treated for 16, 48, and 72 h. Protein (200 g) prepared from frozen
(70 °C) spleens and thymuses were separated by SDS-PAGE, trans-
ferred to membrane, and probed with rabbit anti-human PKR (cross-
reactive with mouse PKR) and goat anti-rabbit IgG-horseradish perox-
idase (HRP, Invitrogen, Carlsbad, CA) and visualized (ECL, Amersham
Biosciences). The same blots were re-probed with goat anti--actin
anti-goat-HRP.
Transient Transfection of Human RNase L—Semi-confluent WISH
(HeLa markers) line was assessed for transfection efficiency using
green fluorescent protein vector (Invitrogen). Semi-confluent WISH
(HeLa markers) was transfected with either pcDNA3.1 vector or
pcDNA3.1 containing full-length human RNase L cDNA. Transfections
were performed in serum-free medium using LipofectAMINE 2000 (Life
Technologies, Inc.) for 6 h followed by replacing the medium with
serum-supplemented medium. After 18 h incubation, human recombi-
nant IFN-2a (500 IU/ml) was added for additional 18 h. PKR levels
were visualized by confocal microscopy using specific antibody to PKR
(Santa Cruz Biotechnology Co., Santa Cruz, CA) or by Western blotting.
Cytosensor Microphysiometer System—Cells were incubated onto
capsule cups for use with a Cytosensor (Molecular Devices, Sunnyvale,
CA) overnight at 37 °C in CO2 incubator. The cells were then trans-
ferred into the silicon-containing sensor chambers of the Cytosensor
and pumped with running buffer comprising low buffered (1 mM phos-
phate) RPMI medium supplemented with 1% BSA at a flow rate of 100
l/min and pump cycle was 2 min. The pump cycle consisted of on and
off cycles: in the off cycle the fluid flow was periodically halted allowing
a build-up of protons (due to acid metabolites as a result of receptor
activation) in the chamber; in the on cycle the pump allowed fluid to be
resumed and the acid was flushed out of the chamber. This cycle was
repeated, and the basal rate of acidification was first measured in the
absence of IFN-. The acidification rate is the output of protons from
the cells. The acidification rates due to IFN- were measured; using a
2-min pump protocol and five repeat cycles, before and after IFN-
treatment to determine the relative changes in acidification rates due to
IFN-. The operation of the apparatus was carried out as recommended
by the manufacturer. Data were processed by software supplied by the
same manufacturer, and data were exported as an Excel spreadsheet
file to GraphPad Prism software (San Diego, CA) for graphics.
Measurement of STAT-1 Tyrosine Phosphorylation—Cells (107) were
extracted in a cold lysis buffer, and the lysates were incubated with
antibody to STAT-1 (Santa Cruz Biotechnology) or normal serum. Im-
munoprecipitates were collected, and proteins were separated by SDS-
PAGE and transferred to nitrocellulose. Blots were washed and blocked
with 4% BSA in PBS for 1 h at room temperature. Antibody to phos-
photyrosine (1 g/ml, Zymed Laboratories) was incubated with the
membranes at 4 °C for 18 h followed by incubation for 2 h with second-
ary horseradish peroxidase-conjugated antibody.
Immunofluorescence and Confocal Microscopy—Cells were formalde-
hyde-fixed and incubated with primary antibody to PKR (Santa Cruz
Biotechnology, 1/50 dilution) for 16 h at 4 °C. The cells were then
washed three times to remove unbound antibodies. Fluorescein isothio-
cyanate secondary antibody (1/100 dilution, 1 h at 37 °C) was subse-
quently used. Cells were then washed three times in PBS, and the
immunofluorescence associated with the cells was imaged using a con-
focal laser scanning microscopy (Leica-Kaki, Saudi Arabia).
RNA Preparation and Northern Blot Analysis—Total RNA was ex-
tracted using TRIzol reagent (Molecular Research Center, Cincinnati,
OH), and 15 g was electrophoresed through a 1.2% agarose/2.2 M
formaldehyde gel. Transfer of RNA was performed overnight using Zeta
Probe nylon membranes (Bio-Rad, Hercules, CA). Membranes were
baked for 2 h in a vacuum oven at 80 °C and prehybridized in Express
Hyb solution (Clontech, Palo Alto, CA) in a Hybaid hybridization oven
at 68 °C (Labnet, Woodbridge, NJ). cDNA probes specific for PKR
mRNA were labeled with [-32P]dCTP (Amersham Biosciences) using a
nick translation kit (Invitrogen). A 40-mer hybridization oligonucleo-
tide probe (Clontech) specific for -actin mRNA was labeled with
[-32P]ATP using T4 polynucleotide kinase (Promega). The blots were
exposed to x-ray film, and the autoradiograms were subsequently de-
veloped. RNA signals were measured with a densitometer (Bio-Rad,
Hercules, CA) and quantitated by ImageMaster image analysis soft-
ware (Amersham Biosciences).
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Quantitative Reverse Transcriptase-PCR—RNase L/ and RNase
L/ MEFs were treated with IFN- (BDBB), 1000 units/ml for 4 h.
Cells were then treated with 5 g/ml actinomycin D for different periods
of time. Cells were harvested, and total RNA was isolated with TRIzol
reagent (Invitrogen). Five g of total RNA was used to prepare cDNA
with Superscript II reverse transcriptase (Invitrogen). Relative levels of
PKR mRNA and glyceraldehyde-3-phosphate dehydrogenase mRNA
were determined using quantitative PCR (Taqman assay) in an ABI
Prism 7700 thermal cycler. PCR was performed for 40 cycles according
to the manufacturer’s protocol. Data analysis was done using Sequence
detector version 1.7 software. Results were expressed as -fold difference
compared with untreated samples. A rodent glyceraldehyde-3-phos-
phate dehydrogenase detection kit was obtained from PE Biosystems.
PKR forward and reverse primers were prepared at Invitrogen. PKR
probe dual-labeled with TAMRA and FAM was synthesized by Inte-
grated DNA Technologies, Inc. (Coralville, IA). Primers and probes
were selected using the Primer Express 1.0 software from ABI, Inc. The
PKR forward primer sequence is 5-GTT AAA GAG CCC GCC GAA
A-3, and the reverse primer sequence is 5-CTG CTG GAA AAG CCA
CTG AAT-3, whereas the Taqman PKR probe is 5-CTG CCG GAA
CAT CCT CTA GCG TTG TC-3.
Statistics, Image Analysis, and mRNA Decay Analysis—For compar-
ison between two groups (columns on figures) the Student’s paired t test
was used. For comparisons among three groups of data (columns on
figures), one-way analysis of variance (ANOVA) was used. Whereas, in
evaluating two groups of data in consideration of other factors (e.g. in
response to different doses of IFN), two-way ANOVA was used. Repeated-
measures ANOVA was used for paired experiments. A paired Student’s
t test for comparison between two sets of paired data was performed.
Two-tailed probabilities were reported. Densitometry, band detection,
background subtraction, and normalization of images was performed
using ImageMaster Software (Amersham Biosciences). The one-phase
exponential decay curve analysis (GraphPad Prism) was used to assess
mRNA decay kinetics. The equation, y  SPAN  exK  PLATEAU,
describes the kinetics of mRNA decay. x is time, and y may be a con-
centration, binding, or response. y begins equal to SPAN  PLATEAU
and decreases to PLATEAU with a rate constant K. The half-life of the
decay is 0.6932/K. SPAN and PLATEAU are expressed in the same
units as the y axis. K is expressed in the inverse of the units used by the
x axis.
RESULTS
PKR Activity in the Presence and Absence of RNase L—Dur-
ing the course of experiments aimed at studying the role of
RNase L in controlling protein synthesis during acute viral
infections, regulation of PKR was monitored in RNase L/ and
RNase L/ mouse embryonic fibroblast (MEF) cell lines by
different methods. Initially, PKR assays were performed with
poly(I)poly(C) as activator and endogenous eIF2 as substrate
in extracts of cells treated with IFN- (1000 units/ml) for dif-
ferent periods of time. Phosphorylation of the  subunit of eIF2
was determined with a specific antibody. In wild type cells,
PKR induction showed transient kinetics following IFN treat-
ment, increasing 4-fold by 6 h and returning to baseline levels
by 12 h (Fig. 1A). In contrast, in the RNase L/ cells, PKR
appeared with extended kinetics, remaining elevated at 36 h
post-IFN addition. There were no changes in levels of total
eIF2 in either cell type during IFN treatment (Fig. 1A, middle
panel).
To confirm these findings, endogenous levels of eIF2 phos-
phorylation were determined in intact cells following EMCV
infections. The levels of phosphorylated eIF2 were transiently
increased in RNase L/ cells following IFN treatment and
infection with EMCV (Fig. 1B). In contrast, levels of phospho-
rylated eIF2 in infected RNase L-null cells peaked about
2-fold higher when compared with wild type cells (Fig. 1). In
addition, after EMCV infections, phosphorylated eIF2 levels
decreased rapidly in wild type cells while remaining elevated in
RNase L/ cells (Fig. 1, A and B).
To rule out indirect effects on eIF2 phosphorylation levels
possibly mediated by phosphatases, we immunopurified PKR
and measured its kinase activity using [-32P]ATP. There was
significantly increased PKR activity as determined by auto-
phosphorylation in extracts of IFN-treated RNase L-null cells
when compared with similarly treated wild type cells (Fig. 1C).
Therefore, PKR activity as measured by these three ap-
proaches was found to be IFN induced to higher levels and for
longer periods of time in the absence of RNase L.
Biological Consequences of RNase L Regulation of PKR on
Viral Protein Synthesis—We chose encephalomyocarditis virus
(EMCV) and vesicular stomatitis virus (VSV), RNA viruses
that are sensitive to IFN-, to determine the biological conse-
quences of RNase L regulation of PKR (16, 17). Profiles of viral
and cellular protein synthesis were determined by pulse label-
ing 1.5 h with [35S]cysteine/methionine in the presence of ac-
tinomycin D to suppress host but not viral transcription (14,
15). IFN treatment inhibited viral protein while restoring syn-
thesis of cellular proteins due to suppression of virus-induced
shut-off of host cell protein synthesis (14, 15, 18, 19). At high
multiplicities of infection (m.o.i.  10 or 100), the viruses
effectively shut-off cellular protein synthesis (Fig. 2, A–C; com-
pare lanes 2 to 1 and lanes 5 to 4). As a result of IFN treatment,
there was partial anti-viral activity in wild type cells but not
FIG. 1. PKR-mediated eIF2 phosphorylation from RNase L/
and RNase L/ MEFs. A, PKR activity was measured by monitoring
the phosphorylation of eIF2. Cells were treated with IFN- (1000
units/ml) for the indicated periods of time except for control. Kinase
assays were for 30 min at 30 °C in the presence of poly(I)poly(C).
Western blots were probed with antibodies specific to Ser-51-phospho-
rylated eIF2 and then detected by HRP-conjugated secondary anti-
body. B, cells were treated with and without IFN- (1000 units/ml)
for 16 h and subsequently infected with EMCV (m.o.i. of 10) for the
indicated periods of time. Cell lysates were assayed for PKR activ-
ity on eIF2 without subjecting to kinase buffer (e.g. no ATP or
poly(I)poly(C)). Western blots for phosphorylated eIF2 were per-
formed as described above. Bands were quantitated densitometrically,
analyzed, and normalized to -actin signals using ImageMaster Soft-
ware. The -fold increase (compared with wild type cell control) was
assessed using -actin-normalized phosphorylated eIF2 levels while
monitoring for total eIF2. C, cells were treated with IFN- (1000
units/ml) for the indicated periods of time except for control. Cell lysates
were used to immunopurify PKR as explained under “Experimental
Procedures.” Kinase reactions with [-32P]ATP and poly(I)poly(C) were
performed with the immunopurified PKR. Subsequently, the PKR were
run on 12% PAGE and visualized by autoradiography.
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enough to completely relieve virus-induced blockage of cellular
protein synthesis (Fig. 2, A–C, lane 3). IFN- alone had no
significant effect on cellular protein synthesis in either cell type
(data not shown). Remarkably, the inhibition of EMCV protein
synthesis (m.o.i. of 10) was more potent in RNase L/ than in
RNase L/ cells (Fig. 2, A and B), and the IFN was able to both
inhibit viral protein synthesis and significantly restore cellular
protein synthesis (Fig. 2, A and B, lane 6). The effect was even
more apparent at the higher m.o.i. of 100 (Fig. 2B). Similar
findings were observed with VSV, viral shut-off of host trans-
lation was prevented by IFN treatment of RNase L-null cells
but not of wild type cells (Fig. 2C). The antiviral activity of
IFN- in wild type and RNase L/ cells was determined in
viral yield reduction plaque assays on indicator cells. Confluent
cells were pretreated with different amounts of IFN- (10–
1000 units/ml) and subsequently infected at an m.o.i. of 10. At
this high m.o.i., the anti-EMCV and VSV action of IFN- was
actually superior (p  0.005, ANOVA) in RNase L/ MEFs
compared with wild type MEFs (Fig. 2, D and E). For example,
at a dose of 1000 units/ml of IFN-, there was 100-fold inhibi-
tion in infectious EMCV yield from RNase L / MEFs com-
pared with only 8-fold inhibition in EMCV yield (p  0.0001,
Student’s paired t test) from wild type cells (Fig. 2D). The
enhanced action against viral protein biosynthesis was condi-
tional on the IFN response, because in the absence of IFN,
virus yield was higher from RNase L-null cells when compared
with wild type cells (Fig. 2F). There was 40- to 50-fold greater
virus yield (p  0.001, Student’s paired t test) in RNase L/
MEFs when compared with wild type MEFs.
PKR Levels in Different Cell Types in Culture and in
Mice—To determine whether the extended kinetics of phospho-
rylated eIF2 in IFN-treated RNase L/ were due to PKR,
levels of PKR protein were determined (Fig. 3A). IFN induction
of PKR was increased with extended kinetics (up to 48 h) in the
RNase L-null cells compared with IFN-treated wild type cells
(Fig. 3A). The PKR protein levels peaked much later than PKR
activity (Fig. 1A) suggesting an additional level of regulation
FIG. 2. Inhibition of viral protein biosynthesis. RNase L/
MEFs and RNase L/ MEFs were treated with mock (cell control; CC),
virus (V), or IFN (1000 units/ml) for 20 h followed by virus (IFNV).
Viruses are EMCV at m.o.i. of 10 (A), EMCV at m.o.i. of 100 (B), and
VSV at m.o.i. 10 (C). Protein synthesis in the presence of actinomycin
D, which inhibits cellular but not viral RNA synthesis, was monitored
as described under “Experimental Procedures”; equal amounts of ly-
sates were loaded onto SDS-PAGE. MW, molecular mass standards
(220, 97.4, 66, 46, 30, 21.5, and 14.3 kDa). Representative autoradio-
grams from three experiments are shown. Arrows indicate positions of
viral proteins. RNase L/ MEFs (black columns) and RNase L/
MEFs (hatched columns) were first treated with IFN- (1000 units/ml,
20 h) except control and infected with EMCV (D) or VSV (E). Infectious
virus yields were measured as described under “Experimental Proce-
dures.” Data are the average  S.E. of three independent experiments
and represented as percentage of control (untreated cells, 100%). F,
virus yield in absence of IFN in RNase L/ MEFs (black columns) and
RNase L/ MEFs (hatched columns) from three experiments. Bars
denote S.E. ***, statistical significance at p  0.001, using Student’s
paired t test when comparing RNase L/ to RNase L/ cell results.
FIG. 3. PKR levels in RNase L-null and wild type cells. A, MEFs
were treated with IFN- (1000 units/ml) for the indicated periods of
time, except for control (0 h), in media containing [35S[methionine. PKR
was immunoprecipitated from cell lysates and visualized in autoradio-
grams. B, confocal microscopy images of PKR induction. Semi-confluent
MEF lines were treated with 1000 units/ml IFN- for 18 h, followed by
fixing and staining with primary antibodies to PKR. The fluorescein
isothiocyanate-labeled secondary antibodies were used to reveal the
primary antibody against PKR and thus indirectly visualize the PKR
protein. C, PKR levels were determined in immunoblots from control or
IFN--treated (2000 units/ml for 24 h) bone marrow macrophages of
RNase L/ (C57BL/6) and RNase L/ mice of the same genetic back-
ground. The lower panel represents graphical representation of data
from the upper panel. PKR levels are shown as a percentage of the
relative levels of tubulin. D, organs (spleen and thymus) were excised
from RNase L/ and RNase L/ mice after intraperitoneal injection of
105 units/ml IFN- for the indicated periods of time. Western blots were
performed using antibodies to PKR and -actin.
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(20). The increased PKR protein levels due to absence of RNase
L were further confirmed with confocal microscopy showing
increased immunostaining of IFN-induced levels of PKR pro-
tein in RNase L/ cells when compared with wild type cells
(Fig. 3B).
To rule out cell type differences and concurrently confirm the
PKR up-regulation in vivo, we performed experiments in pri-
mary cells and in mice organs. Primary macrophages isolated
from bone marrow were cultured in the absence or presence of
IFN- for 24 h (Fig. 3C). Levels of PKR, normalized to tubulin
levels, were modestly increased (1.4- to 1.6-fold) in the RNase
L/ macrophages compared with wild type macrophages, re-
gardless of the presence of IFN (Fig. 3C). IFN induction of PKR
was about 2-fold in RNase L/ and wild type macrophages.
To determine PKR levels in vivo, mice were injected intra-
peritoneal with IFN- (105 units/ml) for different times prior to
sacrificing. Western blots of thymus and spleen proteins were
then probed with antibody to PKR (Fig. 3D). In spleens of the
RNase L/ mice, PKR levels remained elevated (by 1.4-fold)
until 48 h after IFN treatment, in contrast to the RNase L/
mice in which PKR levels returned nearly to baseline at this
time point (Fig. 3D). In thymus glands, PKR reached 1.7-fold
higher levels by 16 h of IFN treatment in the RNase L/ mice
compared with IFN treated wild type mice (Fig. 3D). These
experiments confirm extended PKR levels due to absence of
RNase L in primary cells of different types.
Transient Transfections of RNase L cDNA Inhibit PKR In-
duction in Human Cells—To overexpress RNase L, we used the
human cell line, WISH (HeLa markers), which achieved high
transfection efficiency (85%) as observed with green fluores-
cent protein vector (data not shown). In contrast, the RNase
L-null mouse fibroblasts show low transfection efficiency. The
transient expression of human RNase L cDNA in WISH cells
caused abrogation of IFN-induced PKR protein as assessed
with confocal microscopy using specific antibody to PKR (Fig.
4A). Western blots showed that overexpression of RNase L
caused reductions of constitutive (40% -actin-normalized re-
duction) and IFN-induced PKR protein (70% -actin-normal-
ized reduction) (Fig. 4, B and C). Generally, staining cells with
fluorescence-labeled antibodies (confocal microscopy, Fig. 4A)
gave lower background than Western blotting (Fig. 4B), be-
cause the latter involved denaturation in SDS-PAGE. The
RNase L-induced effect on PKR protein levels correlated with
PKR mRNA levels (Fig. 4, D and E), there was about 60%
-actin normalized reduction in IFN-induced PKR mRNA
levels (Fig. 4, D and E).
RNase L Does Not Regulate PKR Expression and Kinetics by
Influencing IFN Signaling—To elucidate the mechanism of
PKR overexpression and/or prolongation in RNase L/ cells,
we determined PKR mRNA levels and stability of RNase L/
and RNase L/ cells as a function of time of IFN treatment.
Indeed, in RNase L/ MEFs there was enhanced and pro-
longed expression of PKR mRNA in RNase L/ cells in con-
trast to the transient and much lower levels observed in wild
type cells (Fig. 5, A and B). The data showed that PKR mRNA
was induced to about 3-fold higher levels in the RNase L/
cells and remained elevated after 24 h. In contrast, PKR mRNA
levels returned to baseline amounts by 24 h in wild type cells
(Fig. 5, A and B). Levels of -actin mRNA and rRNA, monitored
for comparison, were unaffected by the absence of RNase L
(Fig. 5, A and C). To determine if enhanced IFN signaling was
responsible for the overexpression of PKR mRNA, we moni-
tored tyrosine phosphorylation of STAT-1 and receptor-medi-
ated acidification rates (Fig. 5, D and E). In both cell types,
there was STAT-1 phosphorylation due to IFN treatment, but
no significant differences in the levels of phosphorylated
STAT-1 exist between wild type and RNase L/ cells (Fig. 5D).
Additionally, we used the Cytosensor microphysiometer system
(CMS), which is a biosensor capable of measuring minute
changes in extracellular acidification due to the receptor acti-
vation in living cells (21). Both types of cells were placed in the
CMS in low buffered running medium, and the acidification
rates were monitored until stable baseline rates were obtained.
After equilibrium, cells were exposed to IFN- for 2 min. The
acidification rates due to IFN- treatment were monitored
until returning to baseline (Fig. 5E). We were able to measure
activation of the cells owing to IFN- addition in real-time and
found that peak acidification occurred in only 3.3 min. The
responses to either type of cells are transient, i.e. rapidly return
to the baseline (Fig. 5E). We noted that there were no detect-
able differences in the peaks, acidification rates, or decay of the
IFN response between the wild type and RNase L/ MEFs.
PKR mRNA Stability Is Affected by the Presence or Absence of
RNase L—To determine if the effect of RNase L on PKR mRNA
levels was at the level of mRNA turnover, we blocked transcrip-
FIG. 4. Exogenous expression of RNase L in human cells. Semi-
confluent (75%) WISH (HeLa markers) cells, which assume high trans-
fection efficiency (85% as assessed by green fluorescent protein vec-
tor), were transfected using LipofectAMINE 2000 as described under
“Experimental Procedures” with either pcDNA3.1 vector as a control or
pcDNA3.1 expressing the full-length human RNase L cDNA. After
about 24 h, cells were treated with human IFN-2a (500 IU/ml) for 18 h.
A, cells were stained with anti-PKR followed by fluorescently labeled
antibody for visualization under confocal microscopy. B, cells were used
for Western blotting using antibodies to PKR and -actin. The -fold
differences between untreated vector-transfected and other lanes were
quantitated densitometrically and normalized to -actin signals using
ImageMaster Software (C). Cells were also used for Northern blotting
using cDNA to human PKR and also -actin (D). Lanes from two
independent experiments were quantitated densitometrically and nor-
malized to -actin signals using ImageMaster Software (E). Mean 
S.D. were shown in both graphs. ***, p  0.001 as assessed by ANOVA.
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tion with actinomycin D. There was an initial increase in PKR
mRNA levels in both types of cells when assessed at 1.5 h
probably due to the effect of inhibiting synthesis of labile trans-
acting proteins (Fig. 6). Similar effects are observed for some
AU-rich mRNAs (22, 23). The initial increase in PKR mRNA
amounts was consistently observed (n  4) and thus was not
due to cell culture or experimental variations. We performed
one-phase exponential decay kinetics analysis 1.5 h after addi-
tion of actinomycin D. PKR mRNA decay rates and relative
differences between RNase L/ and RNase L/ cells were
thus determined. The analysis revealed that the half-lives of
PKR mRNA in RNase L/ MEFs was 6.7 h compared with
only 0.8 h in RNase L/ cells (Fig. 6, A and B). Thus, PKR
mRNA had an 8-fold increased half-life in the RNase L/ cells
(Fig. 6B). The constant rate (K) measurements indicated that
the PKR mRNA decay rate is slower in RNase L/ (K  0.1)
than wild type cells (K  0.8). Furthermore, we used independ-
ently derived cell lines from RNase L/ and RNase L/ mice,
both on a genetic background of C57BL/6, to rule out possible
nonspecific cell line differences to assess PKR mRNA stability.
A real-time PCR assay was used to measure the half-life of the
PKR mRNA (Fig. 6C). Relative results were similar to that
obtained by Northern blot assays. Specifically, the half-life of
PKR mRNA was 4.6 h in RNase L/ cells compared with 0.4 h
in wild-type cells.
DISCUSSION
Our findings demonstrate that the 2-5A/RNase L system
negatively regulates PKR expression. A deficiency in RNase L
produces enhanced and prolonged IFN induction of PKR due to
increased half-life of PKR mRNA. The PKR mRNA stabiliza-
FIG. 6. Influence of RNase L on PKR mRNA stability. A, RNase
L/ and RNase L/ MEFs were treated with medium control (lane 1)
or IFN- (1000 units/ml, lane 2) for 4 h followed by actinomycin D (5
g/ml) for various times (lanes 3–6) as indicated. The upper and lower
panels are Northern blots for PKR mRNA and 18 S rRNA, respectively.
B, one-phase exponential decay curves from three independent experi-
ments with S.E. bars are shown; densitometric units (minus back-
ground) are plotted as a function of time after addition of actinomycin
D. C, RNase L/ and RNase L/ MEFs on C57BL/6 genetic back-
ground were treated with IFN- (1000 units/ml) for 4 h and subse-
quently treated with 5 g/ml actinomycin for various intervals. Total
RNA was extracted, reverse-transcribed, and subjected to quantitative
PCR (Taqman assay) for determination of relative levels of PKR mRNA
and glyceraldehyde-3-phosphate dehydrogenase mRNA. One-phase ex-
ponential decay analysis was applied on decaying signals to determine
relative mRNA half-life changes in the two cell types are shown. x is
time, and y is mRNA levels in arbitrary densitometric units. y starts out
equal to SPAN plus PLATEAU and decreases to PLATEAU with a rate
constant K. The half-life of the decay is 0.6932/K  SPAN and PLA-
TEAU are expressed in the same units as the y axis. K is expressed in
the inverse of the units used by the x axis.
FIG. 5. Effects of RNase L on kinetics and signaling of PKR
mRNA induction. RNase L/ and RNase L/ MEFs were treated
with IFN- (1000 units/ml) for the indicated periods of time. A, RNA
was probed for PKR mRNA (upper panel) or 18 S RNA (lower panel). B,
the kinetics of PKR induction are shown graphically as arbitrary den-
sitometric units (minus background). C, Northern blotting using -actin
as a probe (upper panel); loading was verified by ethidium bromide of
18/28 S RNA (lower panel). D, RNase L/ (lanes 1 and 2) and RNase
L/ (lanes 3 and 4) MEFs were treated briefly (15 min) with IFN-
(1000 units/ml; lanes 2 and 4). Cells were lysed and immunoprecipi-
tated with anti-STAT-1 followed by Western blotting using anti-phos-
photyrosine antibody. Equal amounts of lysates were loaded into each
lane as verified by total STAT-1 proteins visualized in the immunoblot
of the gel (lower panel). E, functional response to IFN- using Cytosen-
sor microphysiometer system (CMS) were determined in RNase L/
and RNase L/ MEFs. The graphs show raw data, millivolt changes
over time, whereas smaller graphs (insets) show the acidification rate
(percentage of the baseline) normalized to the baseline (100%). The
vertical arrows indicate the addition of IFN-.
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tion appears to be selective and not due to global mRNA sta-
bilization. Furthermore, in IFN--treated EMCV-infected
RNase L/ cells, elevated levels of PKR correlate with en-
hanced eIF2 phosphorylation and superior inhibition of virus
replication. We consistently observed enhanced and/or prolonged
IFN induction of PKR in the absence of RNase L regardless of the
cell type, genetic background, and whether experiments were
performed in cell culture or in animals. Also, transient expression
of human RNase L in human cells caused selective abrogation of
both constitutive and IFN-induced PKR expression. Taken to-
gether our results suggest that RNase L negatively modulates
the IFN antiviral response and that the transient appearance of
phosphorylated eIF2 under some conditions (e.g. viral infections
at high m.o.i. values) is, at least partly, a result of the negative
feedback mechanism imparted by RNase L.
RNase L Regulation and Inhibition of Viral Protein Synthe-
sis—PKR action mediates translational arrest in host cells
through phosphorylation of eIF-2 and has been previously
implicated in innate immunity to EMCV (24, 25), VSV (26), and
HSV-1 (17). Mice deficient in PKR have somewhat reduced
antiviral responses to IFNs (26, 27), and notably PKR-deficient
cells are prone to HSV-1 infection (17). Thus, PKR-mediated
eIF-2 phosphorylation acts as mechanism in antiviral immu-
nity during the IFN response but has also been implicated in a
variety of responses induced by growth factor deprivation, oxida-
tive stress, the proinflammatory cytokine tumor necrosis fac-
tor-, bacterial lipopolysaccharides, and viral (dsRNA) products
(28–30). The biological consequence of the extended kinetics of
PKR mRNA expression in the absence of RNase L is reflected in
levels of phosphorylated eIF2. Subsequently, this led to the
enhanced inhibition of viral protein synthesis confirming the
importance of the PKR/eIF-2 pathway in controlling viruses.
Nevertheless, alternative antiviral IFN-stimulated pathways
other than PKR might also be affected by the absence of RNase L.
IFN induction of PKR was significantly increased in RNase
L-null cell lines and modestly increased in primary macro-
phages and organs isolated from the RNase L-null animals
compared with similarly treated wild type cells and mice. Mod-
est increases of PKR in animals as opposed to cells in culture
may be due to the in vivo occurrence of low levels of IFN that
would reduce the magnitude of induction. It has been sug-
gested that PKR may participate in the autocrine production of
IFN (24, 26). This may explain the occasional presence of
higher PKR levels in non-IFN-stimulated cells such as those
of primary macrophages isolated from RNase L-null mice. It is
unlikely, however, that increased autocrine production of IFN
is responsible for the extended translational arrest in IFN-
treated RNase L-null cell line, because the viral protein syn-
thesis assay was performed within 4 h of virus infection in the
presence of the transcriptional blocker, actinomycin D. The
exogenous expression of human RNase L in human epithelial
cell line (WISH, HeLa markers) not only extends the findings of
murine cells to human cells, murine and human and murine
RNase L share 64% amino acid homology (31), but also offers a
direct link between RNase L and PKR pathways.
RNase L Regulation of PKR Pathway—Our data show that
the RNase L-mediated regulation of PKR pathway is operative
FIG. 7. A scheme depicting the IFN antiviral response. Upon
infection, viruses shut-off cellular, usually cap-dependent protein syn-
thesis (Fig. 2, A–C; lanes 2 and 5) by several mechanisms, including
disturbance of eIF4G and eIF4E (18, 19, 44, 45) so that cap-independent
viral protein synthesis can proceed (blue block arrow, bottom). As a first
line of defense, the host intracellular enzymes themselves, RNase L and
PKR, act by degrading viral mRNA and inhibiting viral protein synthe-
ses, respectively, as demonstrated by gene knockout studies (12, 17, 25,
27) (Fig. 2F). IFN, which has been produced during the early phase of
infection before cells are compromised by the virus, now comes into play
to protect surrounding cells from viral attack. IFN induces further PKR
and 2,5-oligoadenylate synthetase (OAS). The viral double-stranded
RNA (dsRNA) acts as an activator for both PKR and OAS/RNase L
pathways. dsRNAs binds and activates PKR, which phosphorylates
itself, and subsequently phosphorylates eIF2. The phosphorylated
eIF2 leads to inhibition of viral protein synthesis (Fig. 2, A–D) but may
also cause transient and modest inhibition of cellular protein synthesis.
However, the latter is rapidly restored because inhibition of viral pro-
tein synthesis (a) serves to relieve the virus-induced blockage of protein
synthesis from capped mRNA and as a result rapid replacement of
mRNAs (and proteins) (b) from the host’s genome (Fig. 2, A–C; lanes 3
and 6). When activated by dsRNA, OAS converts ATP to 2,5-oligoad-
enylate (2-5A). This product activates RNase L, which selectively de-
grades viral mRNA (10). In the presence of IFN, RNase L degrades PKR
mRNA as demonstrated by RNase L-knockout studies (Figs. 5 and 6)
and subsequently down-modulates PKR protein (Figs. 3 and 4) and
eIF2 phosphorylation (Fig. 1) to prevent adverse prolonged response
so that healthy cells survive after virus clearance. The dash denotes
inhibitory action.
TABLE I
Antiviral IFN action in cell and animals deficient in
RNase L, PKR, or both
Data are compiled from prior studies (12, 25) (Footnotes a–c) and this
study (Footnote d). Down arrows denote reduction of antiviral action of
IFN whereas up arrows denote increased IFN action in gene- knock-out
models in comparison to wild type controls. Two arrows indicate stron-
ger effects than one arrow whereas 0 denotes either no effect or statis-
tically not significant.
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during IFN response (Fig. 2). This may not be the case, how-
ever, with overexpression of RNase L, which resulted in signif-
icant reduction of both constitutive and IFN-induced PKR. This
may be due to the fact that transfected cells release small
amounts of IFN. Another requirement for the enhanced inhi-
bition of viral protein synthesis is high multiplicity of infection
(m.o.i.). This is concluded from the reconciliation of previous
findings (12, 25) with the findings of this paper. Previously, low
m.o.i. conditions (e.g. m.o.i.  0.01) resulted in viral yields that
were either nearly identical or modestly reduced in IFN-
treated RNase L-null cells compared with wild type cells. In
this report, we used high m.o.i. (10 or 100). The RNA-PKR
interaction is complex and is dependent on concentration,
length, and structure of dsRNA molecules. PKR levels and
optimum interactions are necessary for dimerization of PKR for
full activity (32–36). Thus, at high m.o.i., the combination of
elevated levels of both viral dsRNA intermediates and IFN-
induced PKR accounts for enhanced translational arrest lead-
ing to superior antiviral action of IFN- in RNase L-null cells.
Indeed, m.o.i. of 100 resulted even in stronger translational
arrest than m.o.i. of 10 (Fig. 2, A and B). In acute infections,
high m.o.i., such as those used in this study, may be more
representative of an ongoing acute infection than experiments
with low m.o.i. Very high levels of dsRNA (e.g. 	10 g/ml)
inhibit PKR (35), but these levels do not appear to be obtained
in vivo. Conversely, at low m.o.i., antiviral effects of elevated
PKR may not be observed due to insufficient dsRNA. Table I
summarizes in vivo and cell culture studies on RNase L and
PKR gene disruption experiments, whereas Fig. 7 shows an
overall scheme of the translational arrest during IFN response
to acute virus infection, including the negative regulation of
PKR pathway by RNase L reported here.
Regulation of Cellular mRNA by RNase L—The enhanced
expression of PKR in the absence of RNase L was related to
increased stability of PKR mRNA (Fig. 6). It is unlikely that
these effects are due to changes upstream from mRNA expres-
sions such as signaling, because there were no notable changes
in the functional response of the cells to IFN- as measured by
the microphysiometer system Cytosensor or STAT-1 phospho-
rylation, the latter event being necessary to the STAT-JAK
pathway-mediated transcription of IFN-stimulated genes (37).
For RNase L to degrade mRNAs, it needs to be activated by
2-5A (Fig. 7). These results suggest that 2-5A is present in cells
treated with IFN but in the absence of viral infections. It is
possible that low levels of dsRNA capable of weakly activating
2-5A synthetase are present among cellular RNA (38, 39) lead-
ing to generation of low levels of 2-5A. It was previously sug-
gested that RNase L, itself, does not cause global degradation
of cellular mRNA in intact cells due to low levels of 2-5A, and
only 2-5A at rather high concentrations, is needed to degrade
cellular mRNA such as ribosomal RNA (10, 11, 40). Indeed, our
data show that changes in the PKR mRNA expression are
specific when compared with -actin mRNA and ribosomal
RNA expression. Also, differential display analysis showed
that there were no general cellular mRNA profile changes as a
result of RNase L deficiency.2 Two recent studies showed that
the mRNA stability of ubiquitin-specific protease mRNAs
termed ISG43 and ISG15 mRNA were enhanced in RNase
L-null cells, but this has not been correlated with IFN action
(41). In a separate study (42), it has been concluded that an
effect of RNase L on myoblast determination protein 1 mRNA
levels was relatively specific, because expression of several
other mRNAs was not altered in RNase L inhibitor-transfected
HP68 cells. Also, it has been shown that RNase L degrades
mitochondrial mRNAs for cytochrome b, ATPase 6, and cyto-
chrome oxidase subunit II, but not glyceraldehyde-3-phosphate
dehydrogenase mRNA (which was used as a control) (43).
Taken together, the three studies, including ours, provide evi-
dence for a restricted repertoire of RNase L cellular mRNA
targets as opposed to global cellular mRNA regulation by
RNase L. However, it remains to be determined whether
RNase L selectively affects the turnover of specific sets of
mRNAs in the cell.
Our findings support a novel role for RNase L in the control
of PKR mRNA stability and therefore, in the transient regula-
tion of PKR levels in IFN-treated cells. The control of mRNA
stability is one mechanism that ensures the transient nature of
processes such as immune response, cellular growth, differen-
tiation, and responses to external stimuli. RNase L-induced
transient responses of PKR activation may be a means of avoid-
ing induction of stress pathways (e.g. activation transcription
factor) elicited by eIF2 phosphorylation. Results suggest that
RNase L may mediate the negative regulation of the IFN
response during acute viral infections and perhaps in other
cellular stress responses.
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